Latest News on TFX

Financial News Based On Company


Advertisement
Advertisement

Former Medtronic Executive Joins Teleflex’s Board of Directors

https://www.mpo-mag.com/breaking-news/former-medtronic-executive-joins-teleflexs-board-of-directors/
Teleflex Incorporated has appointed Sean M. Salmon, a former Medtronic executive with over 30 years of experience in the medical device and pharmaceutical industries, to its Board of Directors. Salmon will serve on the newly established Growth and Operating Committee, aiming to support Teleflex's strategic transformation, operational execution, and growth initiatives. His extensive background in various aspects of the medtech industry, including commercial operations, R&D, and financial strategy, is expected to provide valuable insights to the board.

Teleflex Raises Earnings Outlook as Profit Rebounds

https://www.mychesco.com/a/news/business/finance/teleflex-raises-earnings-outlook-as-profit-rebounds/
Teleflex Incorporated has increased its 2026 earnings forecast after a 39% rise in third-quarter adjusted profit, driven by improved operating margins, tariff refunds, and share repurchases. The medical technology company is undergoing a restructuring, divesting businesses, and concentrating on core markets, which is expected to lead to a significant boost in adjusted earnings per share in 2027. The company also announced share repurchases and strategic investments in new medical technology programs.

T. Rowe Price Reveals 6.1% Stake in Teleflex Inc. via SEC Filing

https://kalkinemedia.com/us/news/announcements/t-rowe-price-reveals-61-stake-in-teleflex-inc-via-sec-filing
T. Rowe Price Investment Management, Inc. has disclosed a 6.1% beneficial ownership stake in Teleflex Inc. (NYSE:TFX) through an Amendment No. 8 to its Schedule 13G filing with the SEC. As of September 30, 2026, the firm holds 2,579,248 shares, exercising sole voting power over 2,570,030 shares and sole dispositive power over all its reported shares. This filing underscores T. Rowe Price's position as a significant investor in the medical device company.

Arrow removes products containing spring wire guide components

https://medicalbuyer.co.in/arrow-removes-products-containing-spring-wire-guide-components/
Arrow International, a Teleflex subsidiary, is removing products containing hydrophilic coated Spring Wire Guide (SWG) components due to a potential quality issue. The coating may swell inconsistently, leading to clumping, detachment, and potential particle release into the bloodstream, which could cause serious adverse health consequences including emboli, stroke, or death. As of November 5, 2026, no serious injuries or deaths have been reported.

Endobronchial Tubes Market Size, Share & Forecast 2036

https://www.factmr.com/report/endobronchial-tubes-market
The Endobronchial Tubes Market is projected to grow from USD 416.2 million in 2026 to USD 739.1 million by 2036, at a CAGR of 5.9%. This growth is driven by the increasing demand for advanced airway management in complex thoracic procedures and the adoption of visualization-enabled lung isolation devices. Double-lumen tubes are expected to maintain their lead in product demand, particularly with integrated video capabilities.
Advertisement

Shareholders Can Be Confident That Teleflex's (NYSE:TFX) Earnings Are High Quality

https://simplywall.st/stocks/us/healthcare/nyse-tfx/teleflex/news/shareholders-can-be-confident-that-teleflexs-nysetfx-earning
Teleflex Incorporated (NYSE:TFX) reported healthy earnings, but the stock price remained relatively flat. The article suggests that investors might have overlooked the impact of unusual items that reduced statutory profit by US$56m, which are typically non-recurring. If these unusual expenses do not repeat, Teleflex's future profitability is expected to improve, indicating that the company's earnings potential is stronger than it currently appears.

Teleflex stock hits 52-week high at 156.75 USD

https://www.investing.com/news/company-news/teleflex-stock-hits-52week-high-at-15675-usd-93CH-5022252
Teleflex Inc (NYSE:TFX) has reached a new 52-week high of $156.75, reflecting a 29% year-to-date return and a 42.85% increase over the past year. InvestingPro analysis indicates the stock is still undervalued with a Fair Value of $186.80. This performance follows stronger-than-expected Q3 2026 results and analyst price target increases.

Income Investors Should Know That Teleflex Incorporated (NYSE:TFX) Goes Ex-Dividend Soon

https://simplywall.st/stocks/us/healthcare/nyse-tfx/teleflex/news/income-investors-should-know-that-teleflex-incorporated-nyse
Teleflex Incorporated (NYSE:TFX) is set to go ex-dividend in the next four days, with the dividend of US$0.34 per share payable on December 31st to shareholders who purchase shares before November 16th. The company currently has a trailing yield of 0.9% and pays out 67% of its earnings and 16% of its free cash flow as dividends, indicating reasonable sustainability. However, Teleflex's earnings per share have declined by approximately 21% annually over the last five years, and dividend payments have remained flat over ten years, which raises concerns about long-term dividend growth despite adequate coverage.

Teleflex (NYSE:TFX) Price Target Raised to $167.00

https://www.marketbeat.com/instant-alerts/analyst-teleflex-nyse-tfx-price-target-raised-to-16700-2026-11-09/
Truist Financial has increased its price target for Teleflex (NYSE:TFX) to $167.00 from $142.00, maintaining a "hold" rating, which suggests an 11.04% upside. This decision aligns with a generally positive analyst sentiment, as Teleflex holds a "Moderate Buy" consensus rating and an average price target of $163.30. The medical technology company recently reported strong quarterly earnings of $2.63 per share, significantly surpassing estimates of $1.90, with revenue also slightly exceeding expectations.

Behavioral Patterns of TFX and Institutional Flows

https://news.stocktradersdaily.com/news_release/78/Behavioral_Patterns_of_TFX_and_Institutional_Flows_110926020601_1794251161.html
This report analyzes the behavioral patterns and institutional flows for Teleflex Incorporated (NYSE: TFX), indicating a strong overweight bias across all time horizons. It provides three distinct AI-generated trading strategies: a Multi-Week Position Trading Strategy (LONG), a 1-5 Day Momentum Breakout Strategy (BREAKOUT), and a Tactical/Swing Risk Hedging Strategy (SHORT). The analysis highlights compelling upside potential with no clear resistance levels above the current price.
Advertisement

Teleflex Q3 Earnings Call Highlights

https://www.tradingview.com/news/marketbeat:a0c4887d3094b:0-teleflex-q3-earnings-call-highlights/
Teleflex (TFX) increased its 2026 adjusted earnings per share outlook after a strong third quarter, driven by higher sales, lower interest expenses, and a tariff refund. The company reported a return to growth in its Interventional business, although it faces potential delays in its planned divestiture of the Acute Care and Interventional Urology businesses due to regulatory review. Teleflex also highlighted progress in integrating its acquired Vascular Intervention business and sees significant long-term opportunities for its EZPLAZ product.

Mizuho raises Teleflex stock price target to $160 on margin gains

https://www.investing.com/news/analyst-ratings/mizuho-raises-teleflex-stock-price-target-to-160-on-margin-gains-93CH-5007158
Mizuho has increased its price target for Teleflex Inc. (NYSE: TFX) shares to $160 from $140, maintaining a Neutral rating, due to solid third-quarter 2026 sales performance and expanding operating margins. The medical device maker saw revenue rise 3.0% year-over-year on a constant currency basis and raised its 2026 adjusted earnings per share guidance. The company also completed significant share buybacks, indicating management's confidence in its future.

Teleflex Incorporated (NYSE:TFX) Plans Quarterly Dividend of $0.34

https://www.marketbeat.com/instant-alerts/dividend-teleflex-incorporated-nyse-tfx-plans-quarterly-dividend-of-034-2026-11-05/
Teleflex Incorporated (NYSE:TFX) announced a quarterly dividend of $0.34 per share, payable on December 31st to shareholders of record on November 16th. This represents an annualized dividend of $1.36 and a yield of 0.9%. The company's dividend appears well-covered, with a payout ratio of 9.7% and an expected future payout ratio of 12.5% based on analyst earnings estimates.

Teleflex 3Q 2026: Revenue $567.78M, EPS $22.28 — 10-Q Summary

https://www.tradingview.com/news/tradingview:1eddf4e03e762:0-teleflex-3q-2026-revenue-567-78m-eps-22-28-10-q-summary/
Teleflex reported essentially flat third-quarter revenue year over year at $567.78M, but net income turned positive to $927.43M, driven primarily by a $1.0 billion pretax gain from the sale of its OEM business. Diluted EPS significantly improved to $22.28 from a prior-year loss. The company anticipates completing the sale of its Acute Care and Interventional Urology businesses by year-end 2026 for approximately $530 million.

Teleflex Q3 2026 Earnings Call Transcript

https://www.benzinga.com/news/26/11/62919607/teleflex-q3-2026-earnings-call-transcript
Teleflex reported strong third-quarter 2026 results with a 3% pro forma adjusted constant currency revenue growth and a 25% adjusted operating margin, leading to a 39.2% year-over-year increase in adjusted EPS to $2.63. The company raised its full-year adjusted EPS guidance to $7.50-$7.75, reflecting progress on its transformation, including significant share buybacks and ongoing divestitures. Teleflex is focusing on strengthening its foundation, accelerating organizational effectiveness through a global business unit structure, and elevating growth via increased R&D investment in innovations like Freezolv and EZ Plas.
Advertisement

Teleflex (NYSE:TFX) posts Q3 2026 sales in line with estimates

https://www.tradingview.com/news/stockstory:c9caf144c094b:0-teleflex-nyse-tfx-posts-q3-2026-sales-in-line-with-estimates/
Teleflex (NYSE:TFX) reported Q3 2026 revenue of $567.8 million, up 1.8% year-on-year, meeting Wall Street's expectations. The medical technology company's non-GAAP profit of $2.63 per share significantly beat analysts' consensus estimates by 39.1%. Following these results, management raised its full-year adjusted EPS guidance to $7.63 at the midpoint, an 8.2% increase.

Teleflex (NYSE:TFX) Earnings Beat Faces High Bar as Guidance Quality and Rally Draw Scrutiny

https://www.chartmill.com/news/TFX/Chartmill-57958-Teleflex-NYSETFX-Earnings-Beat-Faces-High-Bar-as-Guidance-Quality-and-Rally-Draw-Scrutiny
Teleflex (NYSE:TFX) reported mixed Q3 2026 results, beating adjusted earnings expectations but slightly missing revenue estimates, leading to scrutiny over its guidance and recent stock rally. Despite raising full-year adjusted EPS guidance, a lower GAAP revenue outlook and the boost from tariff refunds in adjusted results raised questions about the sustainability of growth. The market reacted negatively post-earnings, reflecting profit-taking after a strong prior run, as investors weigh the quality of the earnings beat against modest reported revenue growth and ongoing portfolio changes.

Teleflex Announces Quarterly Dividend

https://finviz.com/news/416643/teleflex-announces-quarterly-dividend
Teleflex Incorporated (NYSE: TFX) announced that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per share of common stock. The dividend is payable on December 31, 2026, to shareholders of record as of November 16, 2026. Teleflex is a global provider of medical technologies, offering solutions in various therapy areas.

Teleflex stock hits 52-week high at 145.97 USD

https://www.investing.com/news/company-news/teleflex-stock-hits-52week-high-at-14597-usd-93CH-4999968
Teleflex Inc. (TFX) reached a 52-week high of $146.33, reflecting a 17.34% increase over the past year and a market capitalization of $6.11 billion. The company has maintained dividend payments for 50 consecutive years and is expected to see net income growth, with recent strong Q2 2026 adjusted earnings and revenue beating estimates. Analyst upgrades and new product developments like Freesolve also contribute to the positive outlook.

Teleflex (TFX) to report earnings tomorrow: here is what to expect

https://markets.financialcontent.com/stocks/article/stockstory-2026-11-4-teleflex-tfx-to-report-earnings-tomorrow-here-is-what-to-expect
Teleflex (NYSE: TFX) is set to announce its earnings results, with analysts expecting a 1.3% year-on-year revenue growth, a significant turnaround from a 27% decrease in the same quarter last year. The company beat revenue and EPS expectations last quarter, and analysts have largely maintained their estimates. While Teleflex has missed Wall Street's revenue estimates multiple times in the past two years, investor sentiment in the healthcare equipment and supplies segment is positive.
Advertisement

Earnings Preview: Teleflex to Report Financial Results Pre-market on November 05

https://www.moomoo.com/news/post/1003073626/earnings-preview-teleflex-to-report-financial-results-pre-market-on
Teleflex (TFX) is scheduled to release its financial results pre-market on November 5. Analysts anticipate the company will report earnings of $3.59 per share, a 7.78% increase from the prior-year quarter. Revenue is projected to reach $748.27 million, marking a 5.75% year-over-year growth.

Teleflex Secures FDA Breakthrough Status for Heart Device

https://www.mychesco.com/a/news/health-medical/teleflex-secures-fda-breakthrough-status-for-heart-device/
Teleflex Incorporated has received FDA Breakthrough Device Designation for its Freesolve Resorbable Magnesium Scaffold for coronary artery procedures. This designation is intended to expedite the regulatory review process for the device, which is already available internationally. Teleflex is currently conducting a pivotal clinical trial to support future U.S. market approval for this temporary vascular implant.

Teleflex Sets November 5 Date for Third-Quarter Results

https://www.mychesco.com/a/news/business/finance/teleflex-sets-november-5-date-for-third-quarter-results/
Teleflex Incorporated (NYSE: TFX) announced it will discuss its third-quarter financial results and provide an operational update on Thursday, November 5, 2026, at 8 a.m. Eastern Time. The company, a Wayne-based medical technology firm, will host a conference call accessible by telephone or live audio webcast to review its performance across various medical device markets. An audio replay will be available starting 11 a.m. Eastern Time on November 5.

Teleflex Incorporated (TFX) Seasonal Returns Chart - Yahoo Finance

https://ca.finance.yahoo.com/quote/TFX/seasonality/
The article provides a seasonal returns chart for Teleflex Incorporated (TFX), showing the average monthly price return from 2016 to 2026. It includes current stock information, indicating a closing price of $139.77 with a slight decrease, and after-hours trading showing no change. The content also features market data for Canada, US, Europe, Asia, cryptocurrencies, and commodities.

Teleflex Inc. stock underperforms Friday when compared to competitors

https://www.marketwatch.com/data-news/teleflex-inc-stock-underperforms-friday-when-compared-to-competitors-48bddbf0-1c5c463f5368?mod=goog_fin_scmw
On Friday, Teleflex Inc. (TFX) shares decreased by 1.15% to $139.77, performing worse than the broader market which saw the S&P 500 Index fall 1.82% and the Dow Jones Industrial Average decline 1.09%. The stock closed 3.61% below its 52-week high of $145.00 reached on August 6th.
Advertisement

Teleflex Incorporated (TFX) Seasonal returns chart

https://uk.finance.yahoo.com/quote/TFX/seasonality/
The article displays a seasonal returns chart for Teleflex Incorporated (TFX), showing the average monthly price return between 2016 and 2026. As of the time of publication, Teleflex Incorporated's stock was priced at 141.65 USD, up 0.30% from the previous close.

Teleflex Inc. stock outperforms competitors on strong trading day

https://www.marketwatch.com/data-news/teleflex-inc-stock-outperforms-competitors-on-strong-trading-day-287a5215-5e4b47859b79?mod=goog_fin_scmw
Teleflex Inc. (TFX) shares rose 1.73% to $141.39 on Thursday, bucking a broader market downturn that saw the S&P 500 and Dow Jones Industrial Average decline. The company's stock closed 2.49% below its 52-week high of $145.00, achieved on August 6th. This performance highlights Teleflex's resilience in a challenging trading session.

Wayne’s Teleflex Receives FDA Breakthrough Device Designation for Freesolve™ Resorbable Magnesium Scaffold

https://biobuzz.io/news/waynes-teleflex-receives-fda-breakthrough-device-designation-for-freesolve-resorbable-magnesium-scaffold/
Teleflex, a medical technology company based in Wayne, Pennsylvania, has been granted FDA Breakthrough Device Designation for its Freesolve™ Resorbable Magnesium Scaffold (RMS) for percutaneous coronary intervention (PCI). This designation aims to expedite the review process for devices treating life-threatening conditions and marks the second such designation for the Freesolve platform. The Freesolve™ RMS is designed to support artery walls temporarily before dissolving, offering an alternative to permanent implants and drug-coated balloons.

FDA Device Breakthrough Might Change The Case For Investing In Teleflex Stock (TFX)

https://sg.finance.yahoo.com/news/fda-device-breakthrough-might-change-001309026.html
Teleflex (TFX) recently received FDA Breakthrough Device Designation for its Freesolve Resorbable Magnesium Scaffold for PCI, a significant R&D asset aimed at treating serious coronary disease. This designation strengthens Teleflex's long-term product pipeline, particularly in cardiology, although the company still needs to address near-term execution challenges like the BIOTRONIK Vascular Integration and its restructuring program. The news supports a more optimistic outlook for Teleflex's future earnings and revenue projections, but investors must weigh this against ongoing operational risks.

Teleflex Inc. stock outperforms competitors on strong trading day

https://www.marketwatch.com/data-news/teleflex-inc-stock-outperforms-competitors-on-strong-trading-day-cfc27f12-e1f7457d6088?mod=goog_fin_scmw
Teleflex Inc. (TFX) shares rose 1.61% to $139.00 on Tuesday, marking its second consecutive day of gains. The stock's performance outpaced its competitors on a strong trading day for the broader market, with both the S&P 500 and Dow Jones Industrial Average also seeing increases.
Advertisement

FDA approves Teleflex cardiac treatment

https://pennbizreport.com/news/33852-fda-approves-teleflex-cardiac-treatment/
The FDA granted a breakthrough device designation to Teleflex Inc.'s Freesolve Resorbable Magnesium Scaffold (RMS), a drug for treating percutaneous coronary intervention. This designation highlights the drug's potential for more effective treatment of life-threatening diseases and marks a significant step in bringing it to U.S. patients. Freesolve RMS aims to reduce the need for permanent implants and offers an alternative to drug-coated balloons, supporting the vessel wall temporarily.

Teleflex Completes Enrollment in Coronary Scaffold Trial

https://www.mychesco.com/a/news/health-medical/research/teleflex-completes-enrollment-in-coronary-scaffold-trial/
Teleflex Incorporated has completed enrollment of 102 patients in a European clinical study (BIOMAG-LL) evaluating longer versions of its Freesolve Resorbable Magnesium Scaffold. This trial aims to assess the safety and clinical performance of 35-millimeter and 40-millimeter dissolvable coronary scaffolds for treating extensive coronary artery disease, potentially offering an alternative to permanent stents. The study is a significant step in expanding treatment options for longer coronary lesions and reducing reliance on permanent implants, with results anticipated to inform further product development and market expansion.

Teleflex Incorporated Estimates – NYSE:TFX

https://www.tradingview.com/symbols/NYSE-TFX/financials-estimates/
This page on TradingView provides financial estimates and actuals for Teleflex Incorporated (NYSE: TFX). Users can explore reported financial data and analyst estimates across the income statement, balance sheet, cash flow statement, and valuation metrics, comparing actual results with average, high, and low estimates, and visualizing trends over time. The platform also offers disclaimers stating that the information is not investment advice and encourages users to do their own research.

Teleflex Incorporated (TFX) stock price, news, quote and history

https://uk.finance.yahoo.com/quote/TFX/
This article provides a comprehensive overview of Teleflex Incorporated (TFX), including its current stock price, recent performance, key financial metrics, and company profile. It details the company's various medical devices for critical care and surgical applications, analyst ratings, and historical earnings trends. The information aims to give investors a snapshot of TFX's market position and financial health.

Teleflex Inc. stock outperforms competitors on strong trading day

https://www.marketwatch.com/data-news/teleflex-inc-stock-outperforms-competitors-on-strong-trading-day-bfa88b9d-1ff6f4854a86
Teleflex Inc. (TFX) shares rose 4.74% to $136.58 on Thursday, outperforming the broader market which saw mixed results with the Dow Jones Industrial Average slightly up and the S&P 500 Index down. The company's stock closed 5.81% below its 52-week high of $145.00 reached in August.
Advertisement

Teleflex’s Freesolve Scaffold Earns FDA Breakthrough Nod for PCI

https://www.mpo-mag.com/breaking-news/teleflexs-freesolve-scaffold-earns-fda-breakthrough-nod-for-pci/
Teleflex's Freesolve resorbable magnesium scaffold has received its second FDA Breakthrough Device Designation for its use in percutaneous coronary intervention (PCI), recognizing its potential to meet unmet clinical needs. The device, which uses a proprietary magnesium alloy and bioabsorbable coating, is designed to support vessels during and after implantation, with 99% of the magnesium resorbed within 12 months. This designation could expedite its development and review, offering an alternative to permanent coronary implants and drug-coated balloons in the U.S. market.

Teleflex gains FDA breakthrough designation for Freesolve coronary scaffold

https://mugglehead.com/teleflex-freesolve-fda-breakthrough-coronary-scaffold/
Teleflex Incorporated received FDA Breakthrough Device designation for its Freesolve resorbable magnesium coronary scaffold system. This designation will expedite the development and review process for the investigational device, which is currently undergoing a pivotal 1,859-patient trial. Freesolve, already commercially available in some international markets, provides temporary vessel support for percutaneous coronary intervention.

FDA grants Teleflex breakthrough device status for coronary scaffold

https://www.streetinsider.com/Corporate+News/FDA+grants+Teleflex+breakthrough+device+status+for+coronary+scaffold/27218612.html
Teleflex Incorporated announced that its Freesolve™ Resorbable Magnesium Scaffold has received Breakthrough Device Designation from the U.S. Food and Drug Administration. This designation aims to accelerate the development and review of devices addressing unmet clinical needs for life-threatening conditions in percutaneous coronary intervention. The Freesolve scaffold, which is bioabsorbable, is currently being evaluated in a pivotal trial to support future FDA approval in the United States.

Teleflex wins FDA breakthrough status for heart scaffold device

https://www.investing.com/news/company-news/teleflex-wins-fda-breakthrough-status-for-heart-scaffold-device-93CH-4965409
Teleflex Incorporated has received Breakthrough Device Designation from the FDA for its Freesolve Resorbable Magnesium Scaffold for percutaneous coronary intervention. This designation aims to expedite the development and review of the device, which is designed to provide temporary vessel support and reduce the need for permanent implants. The Freesolve device is currently available in several international markets and is undergoing a pivotal trial to support a future FDA Premarket Approval application in the U.S.

Laparoscopic Access Instruments Market To 2035: Growth Momentum Builds on MIS Adoption - News and Statistics

https://www.indexbox.io/blog/laparoscopic-access-instruments-market-forecast-to-2035-driven-by-rising-minimally-invasive-surgery-adoption/
The global laparoscopic access instruments market is projected to grow at a compound annual growth rate (CAGR) of 5.8% from 2026 to 2035, driven by the increasing adoption of minimally invasive surgical (MIS) procedures. Key factors fueling this growth include rising chronic disease prevalence, technological advancements in instruments, and expanding healthcare infrastructure in emerging economies. While North America and Europe maintain significant market shares, Asia-Pacific is anticipated to be the fastest-growing region.
Advertisement

Truist cuts Teleflex target from USD 150 to USD 142 for Teleflex stock

https://www.ad-hoc-news.de/boerse/news/nebenwerte/truist-cuts-teleflex-target-from-usd-150-to-usd-142-for-teleflex-stock/70373169
Truist has lowered its price target for Teleflex Inc. from USD 150 to USD 142, while maintaining a Hold rating due to a mixed third-quarter setup and pressure on future estimates. Despite the target cut, Teleflex reported a 28.9% year-over-year increase in second-quarter revenue to USD 570.33 million. The company's stock was trading at EUR 115.85 at Lang & Schwarz on October 20, 2026, ahead of its next earnings report scheduled for October 29, 2026.

REG - Competition and Mkts - Merger Update: Intersurgical / Teleflex

https://www.tradingview.com/news/reuters.com,2026-10-20:newsml_RST1142Za:0-reg-competition-and-mkts-merger-update-intersurgical-teleflex/
The Competition and Markets Authority (CMA) has issued an invitation to comment on the anticipated acquisition of Teleflex Incorporated's acute care and interventional urology businesses by Intersurgical AG. This move follows the planned acquisition of control over Intersurgical AG by Armira Capital and TA Associates. The CMA is seeking initial views from interested parties on the potential impact of this transaction on competition in the UK before launching its formal investigation, with comments due by November 3, 2026.

Truist cuts Teleflex target to USD 142 from USD 150 for Teleflex stock

https://www.ad-hoc-news.de/boerse/news/nebenwerte/truist-cuts-teleflex-target-to-usd-142-from-usd-150-for-teleflex-stock/70353342
Truist has lowered its price target for Teleflex Inc. (TFX) to USD 142 from USD 150, maintaining a Hold rating. This decision follows a similar move by Mizuho and comes ahead of Teleflex's third-quarter 2026 earnings report, scheduled for October 29, 2026. Analysts cite concerns over procedure volumes and capital spending, despite relatively stable US end markets.

Teleflex Incorporated (TFX) Stock Forecasts

https://ca.finance.yahoo.com/research/reports/ARGUS_4294_QuantitativeReport_1791936000000
An Argus report from October 14, 2026, provides a market assessment for Teleflex Incorporated (TFX), a medical device manufacturer. The report includes a price target and a summary of the company's business in hospital supplies and medical devices, particularly in bloodstream/vascular and surgical areas. The article also lists other related analyst reports.

Teleflex Inc. stock outperforms competitors on strong trading day

https://www.marketwatch.com/data-news/teleflex-inc-stock-outperforms-competitors-on-strong-trading-day-93e81c47-83ce5e6f1d69?mod=goog_fin_scmw
Teleflex Inc. (TFX) shares rose 1.72% to $130.43 on Friday, outperforming the broader market which saw the S&P 500 Index and Dow Jones Industrial Average decline. This marks the second consecutive day of gains for the stock, despite a generally poor trading session.
Advertisement

Teleflex completes 102-patient study enrollment for Teleflex stock

https://www.ad-hoc-news.de/boerse/news/nebenwerte/teleflex-completes-102-patient-study-enrollment-for-teleflex-stock/70328944
Teleflex announced the completion of enrollment for its BIOMAG-LL clinical study with 102 patients across 14 European centers. The study evaluates resorbable magnesium scaffolds for coronary lesions, aiming to expand clinical evidence for Teleflex's interventional cardiology portfolio. Despite this operational milestone, the company has lowered its 2026 revenue-growth outlook while simultaneously increasing its adjusted earnings-per-share guidance.

Teleflex Inc. stock outperforms competitors despite losses on the day

https://www.marketwatch.com/data-news/teleflex-inc-stock-outperforms-competitors-despite-losses-on-the-day-e382e8c8-2153c65c69dc?mod=goog_fin_scmw
Teleflex Inc. (TFX) shares decreased by 1.00% on Tuesday, closing at $124.44, despite an overall negative day for the stock market where the S&P 500 Index and Dow Jones Industrial Average also saw declines. This fall ended a two-day winning streak for Teleflex.

Teleflex Inc Share Price - TFX, RNS News, Articles, Quotes, & Charts (NYSE:TFX)

https://www.proactiveinvestors.com/companies/6369/Teleflex-Inc
This page provides an overview of Teleflex Inc (NYSE:TFX), a medical technology company. It includes current stock information such as price, day change, market cap, and 52-week high and low. The article also lists recent news regarding Teleflex, including past acquisitions and divestitures, and describes the company's business segments and product offerings.

Teleflex Incorporated (TFX) Stock forecasts

https://uk.finance.yahoo.com/research/reports/ARGUS_4294_QuantitativeReport_1789516800000
This page is a placeholder for Teleflex Incorporated (TFX) stock forecasts, but it currently displays an error preventing the data from loading. It is part of the Yahoo Finance platform, which offers various financial tools and market data.

Teleflex completes enrollment in BIOMAG-LL magnesium scaffold study

https://www.streetinsider.com/Corporate+News/Teleflex+completes+enrollment+in+BIOMAG-LL+magnesium+scaffold+study/27173653.html
Teleflex Incorporated has successfully completed patient enrollment for its BIOMAG™-LL Clinical Study, evaluating longer lengths of the Freesolve™ Resorbable Magnesium Scaffold for coronary lesions. The study, involving 102 patients across 14 European centers, aims to assess the scaffold's performance at 12 months with extended follow-up. This development is crucial for expanding treatment options for patients with longer coronary lesions and the study data will inform future approvals.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement